CSL completes Novartis influenza vaccine business acquisition

CSL completes Novartis influenza vaccine business acquisition

Melbourne, Australia — 03/08/2015

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July, closing of the transaction will allow CSL to integrate the influenza vaccines division with its subsidiary, bioCSL. The combined business will create the second largest influenza vaccine business in the US$4 billion global industry and will have manufacturing plants in the US, UK, Germany and Australia, a commercial presence in approximately 20 countries, a differentiated product portfolio and strong pandemic and pre-pandemic franchises.

Download this release: 
PDF icon CSL completes Novartis influenza vaccine business acquisition (0.30Mb)


For further information, please contact: 

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Australia Media:
  Sharon McHale
  Head of Public Affairs
  CSL Limited
  Phone: +613 9389 3425
  Mobile: +614 0997 8314
  Email: sharon.mchale@csl.com.au
US & Europe Media:
  Natalie de Vane
  Snr. Director Corporate Communications
  CSL Behring
  Phone: +1 610 878 4468
  Email: natalie.devane@cslbehring.com
 
.

© 2016 CSL Limited